Back to News
Market Impact: 0.3

Validea Detailed Fundamental Analysis

CVSNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechConsumer Demand & RetailMarket Technicals & FlowsInvestor Sentiment & Positioning
Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates that CVS Health Corp. (CVS) receives a high rating (87%) based on their Multi-Factor Investor model, which is based on the investing strategy of Pim van Vliet. The model favors low volatility stocks with strong momentum and high net payout yields, and CVS passes most of the strategy's tests, particularly in market cap and standard deviation, though it's neutral in twelve minus one momentum and net payout yield. Van Vliet's research suggests that low volatility stocks outperform high volatility stocks with less risk.

Analysis

CVS Health Corp (CVS) has garnered an 87% rating from Validea's Multi-Factor Investor model, a strategy developed by Pim van Vliet that prioritizes low volatility stocks exhibiting strong momentum and high net payout yields. This score signifies a notable interest from the model, as scores above 80% are considered indicative of such. CVS, a large-cap growth stock in the Retail (Drugs) sector, successfully met the model's criteria for market capitalization and standard deviation, aligning with the strategy's preference for low volatility. However, the company registered 'Neutral' for 'Twelve Minus One Momentum' and 'Net Payout Yield', suggesting these factors are not currently strong drivers for the stock under this specific model, despite a 'Pass' on the final rank. The underlying investment philosophy of Pim van Vliet posits that low volatility stocks can offer superior returns with reduced risk, a concept supported by his research. The general sentiment surrounding this report is moderately positive (0.55), with a specific sentiment score of 0.7 for CVS, reflecting an optimistic tone regarding its fit within this investment framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo